ENLT
Contact us

Reimbursement applications

For pharmaceuticals, medical devices and health care services in the Baltic States.

Contact us
  1. Record
  2. Curve
  3. Application

New: health data analysis

Our newest service: analyses of secondary health data from the State Data Agency, for a reimbursement application or as a standalone study for any organisation.

  1. Record
  2. Curve
  3. Application

A dossier ready to submit

From pre-assessment through every application part to the final package, with support until the evaluation is complete.

  1. Record
  2. Curve
  3. Application

Services

From pre-assessment to submission

Reimbursement applications

Preparation and delivery of complete, submission-ready applications for pharmaceutical companies and their authorised representatives.

  1. Pre-assessment review

    • Guidance on and review of materials for the application
    • Situation analysis and assessment of reimbursement potential against payers' expectations: strength of evidence, uncertainties, indirect comparisons, cost-effectiveness
    • Presentations and clarification discussions

  2. Application parts

    • Clinical effectiveness
    • Cost-effectiveness analysis: report and CEM for submission
    • or cost-minimisation analysis: report and xlsx
    • Budget impact analysis: report and xlsx

  3. Final presentation

    • For the client's approval, built on payers' evaluation criteria

  4. Submission package

    • The final set of application files, ready to submit

  5. Evaluation support

    • Consultancy throughout the evaluation process
    • Responses to authority questions on clinical and pharmacoeconomic documentation

Data analysis

Answers based on Lithuanian health data

Our newest service, open to any organisation: pharmaceutical companies, researchers or anyone with a health data question. In reimbursement applications, it can defend the inputs that decide the ICER, such as survival on current standard of care, subsequent treatments and treatment duration.

0255075100061218243036Months since treatment startSurviving, %
Lithuanian patients (RWD)Clinical trial armTicks mark censored patients
At risk061218243036
RWD4203512811781096031
Trial2602381981318238-

Do Lithuanian outcomes match the clinical trial data?

We build a comparable cohort by indication and line of therapy, then estimate survival from treatment start with proper handling of censoring. Hover over the chart.

GroupnMedian, mo.12 mo.24 mo.
RWD42022.472%48%
Trial26025.781%55%

Illustrative, simulated data.

Paper map of Estonia, Latvia and Lithuania

Across the Baltic States

Applications for reimbursement of pharmaceuticals, medical devices and health care services in Lithuania, Latvia and Estonia. In Lithuania, we have worked with the majority of pharmaceutical companies for nearly 20 years.

  • Lithuania
  • Latvia
  • Estonia

Team

The team behind every dossier

Our professional experience covers health system research, management and analytics. Specialising in HTA, we also analyse the economic burden of major diseases and the related big data. Together, the team covers every part of a reimbursement dossier.

Paper dossier tied with a blue ribbon

  • Eglė

    PhD, MPH

    Cost-effectiveness modelling and budget impact

    Health economics and HTA expert who combines scientific expertise with a practical understanding of healthcare systems. Her professional experience spans health technology assessment, economic modelling, real-world evidence (RWE), market access, and reimbursement strategy.

  • Žilvinas

    MD, PhD, MPH

    Pre-assessments and clinical evidence

    Extensive experience across all areas of the health care system, including HTA. He leads preliminary application reviews (pre-assessments) of the evidence and reimbursement potential. As a physician and public health professional, he specialises in the comparative efficacy, safety and clinical effectiveness parts of reimbursement applications.

  • Laura

    MPH

    Systematic literature review and data analysis

    Collects and updates the clinical and economic evidence needed for Lithuania, performs data analyses and structures separate parts of reimbursement applications.

  • Mangirdas

    Data analyst

    State Data Agency requests and quantitative analysis

    Drafts data requests to the State Data Agency (Valstybės duomenų agentūra) and carries out the quantitative analysis of the requested data, for the economic part of reimbursement applications and for standalone analyses.

Client needs form

Tell us about your product or data question and your timeline, and we will get back to you.

UAB HTA Solutions
Company code 305516899
VAT code LT100013066017

Topic